Browse the evidence

Natural products from plants are a promising source for new lead structures for drug discovery targeting obesity.

Practitioners may consider exploring natural plant metabolites for obesity treatment.

A new classification of patients with diabetes mellitus into clusters can assess the risk of developing diabetic nephropathy.

Practitioners can use this classification to better assess nephropathy risk in diabetic patients.

Systematic screening for advanced fibrosis related to MASLD is recommended for patients with T2D.

Healthcare professionals should implement systematic screening for liver fibrosis in diabetic patients.

Health care expenditures increased by $80 per month during the 13- to 24-month period, excluding the cost of semaglutide.

Practitioners should consider potential increases in health care costs when prescribing semaglutide.

HEC-CG115 has an optimal safety profile with a no observed adverse effect level of 3 mg/kg.

HEC-CG115 appears to be a safe option for therapeutic use.

Body and fat mass and blood glucose levels are not regulated, controlled, or defended.

Practitioners should reconsider the concepts of regulation and control in metabolism when addressing obesity.

The 'Invisible Hand of Metabolism' illustrates unregulated behavior of cells affecting physiological states.

Understanding cellular behavior can help in developing strategies for obesity management.

Treatment-limiting gastrointestinal side effects occurred in 16.7% of patients.

Clinicians should monitor for gastrointestinal side effects in patients taking semaglutide.

The translational application of browning agents in humans faces challenges.

Practitioners should be aware of the limitations when considering browning agents for treatment.

People with MASH and clinically significant fibrosis are at risk of progressing to cirrhosis and hepatocellular carcinoma.

Monitoring and intervention are crucial for patients with MASH and fibrosis.

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately one-third of the population.

Health practitioners should be aware of the high prevalence of MASLD in their patient populations.

There is an urgent need for fundamental research to understand the mechanisms of metabolic disorders and cardiovascular disease.

Invest in research to better understand and treat metabolic and cardiovascular diseases.

Collagen and free amino acid ingestion did not significantly increase myofibrillar protein synthesis rates in either rested or exercised legs.

Collagen and amino acid supplementation may not enhance muscle protein synthesis in healthy individuals post-exercise.

Collagen and free amino acid ingestion did not significantly increase muscle connective protein synthesis rates in either rested or exercised legs.

Collagen and amino acid supplementation may not enhance connective tissue protein synthesis in healthy individuals post-exercise.

Rifampicin enhances lipolysis and suppresses lipogenesis in adipocytes.

Rifampicin may be useful in promoting fat loss by altering lipid metabolism.

Obesity is characterized by adipose tissue dysfunction, insulin resistance, chronic low-grade inflammation, and gut microbiota dysbiosis.

Understanding these characteristics can help in developing targeted interventions for obesity.

Greater achieved weight loss during the landmark period did not show a consistent association with lower post-landmark cardiovascular risk.

Weight loss alone may not be sufficient to reduce cardiovascular risk, emphasizing the importance of medication dosage.

The study drug was well tolerated, and no serious adverse events were reported.

Practitioners can consider semaglutide safe for use in healthy individuals based on this study.

Research is being pursued to investigate glucose-lowering agents for their anti-inflammatory, neuroprotective, and lipotoxic reduction effects.

Future research may expand the therapeutic applications of these medications.

Obstacles in integrating injectables into existing regimens include restricted access to information and insufficient training.

Training and access to information are crucial for effective diabetes management.

Tirzepatide can cause acute hepatocellular liver injury in patients.

Clinicians should monitor liver function in patients using tirzepatide.

Symptoms of liver injury resolved and liver enzymes normalized within 3 weeks of presentation.

Patients may recover from tirzepatide-induced liver injury with appropriate monitoring.

HMB supplementation failed to demonstrate significant benefits for muscle strength (SMD = -0.22, 95% CI: -0.57, 0.12) or mass outcomes (MD = 0.05, 95% CI: -0.33, 0.44).

HMB supplementation may not be effective for improving muscle strength or mass in older adults.

The study failed to observe a statistically significant difference in the primary efficacy measure of ≥20 mg/dl difference in the 2-h OGTT at 3 months.

The lack of significant difference suggests that sitagliptin may not be effective in improving glucose tolerance in this population.